Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine
This study has been completed.
Sponsored by: Rambam Health Care Campus
Information provided by: Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT00392964
  Purpose

There is substantial, continuing, and unexplained rise in prescribing of proton pump inhibitors. It is unknown whether their use in practice has corresponded to their licensed indications.

Although the indications for H2RA or PPI administration in the treatment of acid-related diseases and the prevention of gastric mucosal damage have been well defined in the medical literature, the perception of benefit from their use frequently tends to be extrapolated to all patients in general, leading to an excessive consumption of these drugs in general practice.

To date, however, little has been published with regard to the overall use or misuse of these drugs in hospital populations in ischemic heart disease patients as a secondary prevention to Aspirin use.

We will undertake a 6-months retrospective survey (about 1200 patients) to evaluate the use of acid-suppressive medications in the general internal medicine ward of Rambam Hospital.

We will extract all records of prescribing of a proton pump inhibitor within Rambam Hospital computerized patients file program (Premetheuos) in period of half year, categorized and analyze them using statistical X2 test.


Condition
Ischemic Heart Disease

MedlinePlus related topics: Heart Diseases
Drug Information available for: Acetylsalicylic acid
U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Longitudinal, Defined Population, Retrospective Study
Official Title: Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine

Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 1200
Study Start Date: January 2006
Study Completion Date: November 2006
Detailed Description:

Dyspeptic symptoms are a common presenting complaint, and there is continuing debate about management. Acid suppressant drugs, the most potent of which are proton pump inhibitors, are often prescribed, and it has been suggested that proton pump inhibitors are probably too widely prescribed for minor symptoms, and the cost implications of this are clear. There is substantial, continuing, and unexplained rise in prescribing of proton pump inhibitors. It is unknown whether their use in practice has corresponded to their licensed indications.

Although the indications for H2RA or proton pump inhibitor administration in the treatment of acid-related diseases and the prevention of gastric mucosal damage have been well defined in the medical literature, the perception of benefit from their use frequently tends to be extrapolated to all patients in general, leading to an excessive consumption of these drugs in general practice.

In addition, Physicians, nowadays tend to prescribe proton pump inhibitors for cardiac patients who use aspirin as secondary prevention of their illness.

To date, however, little has been published with regard to the overall use or misuse of these drugs in hospital populations, or to the fall-out of hospital prescriptions in general practice and none has been published regarding its use in ischemic heart disease patients as a secondary prevention to Aspirin use.

We will undertake a 6-months retrospective survey (about 1200 patients) to evaluate the use of acid-suppressive medications in the general internal medicine ward of Rambam Hospital, a large teaching hospital in Northern Israel; as well as the appropriateness of their prescription to the licensed indications, while dividing them to subgroups of ischemic heart disease patients.

We will extract all records of prescribing of a proton pump inhibitor within Rambam Hospital computerized patients file program (Premetheuos) in period of half year, categorized and analyze them using statistical X2 test.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ischemic Heart Disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00392964

Locations
Israel
Rambam: Health Care Campus
Haifa, Israel, 31096
Rambam Health Care Campus
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Zaher S Azzam, MD Acting Director of Internal Medicine "B"
  More Information

Study ID Numbers: ZSA2438CTIL
Study First Received: October 25, 2006
Last Updated: April 10, 2007
ClinicalTrials.gov Identifier: NCT00392964  
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:
Antacids
Proton pump inhibitors
aspirin
ischemic heart disease
Dyspepsia

Study placed in the following topic categories:
Heart Diseases
Aspirin
Myocardial Ischemia
Vascular Diseases
Ischemia
Dyspepsia

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009